Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tongrentang CoSHSE:600085 -0.41%81 EV-to-EBIT is 17.61 as of Aug. 27, 2026, which is 9% below its 10-year median of 19.45. GuruFocus rates SHSE:600085 with a GF Score™ of 81/100 and a GF Value™ of ¥35.95 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 691 Drug Manufacturers companies, Beijing Tongrentang Co ranks worse than 53.69% on this metric.
Beijing Tongrentang Co (SHSE:600085) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Beijing Tongrentang Co's Enterprise Value for the quarter that ended in Mar. 2026 was ¥37,938 Mil.
Beijing Tongrentang Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,895 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tongrentang Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tongrentang Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Tongrentang Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Beijing Tongrentang Co's EV-to-EBIT falls into.
Beijing Tongrentang Co's current Enterprise Value is ¥33,371 Mil.
Beijing Tongrentang Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,895 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tongrentang Co (SHSE:600085) has a EV-to-EBIT of 17.61 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beijing Tongrentang Co and its competitors. This is near median its historical median of 19.45. Over the past decade, Beijing Tongrentang Co's EV-to-EBIT has ranged from 13.55 to 28.24. According to the industry distribution chart, Beijing Tongrentang Co ranks #371 out of 691 companies in the Drug Manufacturers industry, placing it in the top 53.7%.
Is Beijing Tongrentang Co's EV-to-EBIT too high?
Beijing Tongrentang Co's current EV-to-EBIT of 17.61 is near median its 10-year median of 19.45. Over the past 10 years, this metric has ranged from a low of 13.55 to a high of 28.24. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Beijing Tongrentang Co's value of 17.61 is 11.7% above this industry median. Based on the distribution chart, Beijing Tongrentang Co ranks #371 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beijing Tongrentang Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tongrentang Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Tongrentang Co ranks #371 out of 691 companies for EV-to-EBIT. This places Beijing Tongrentang Co in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Beijing Tongrentang Co's value of 17.61 is 11.7% above this benchmark. Historically, Beijing Tongrentang Co's own EV-to-EBIT has ranged from 13.55 to 28.24 over the past decade. While the company's 10-year median is 19.45 vs. the industry median of 15.77, Beijing Tongrentang Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tongrentang Co's current EV-to-EBIT of 17.61 is 11.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beijing Tongrentang Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tongrentang Co's current EV-to-EBIT is 17.61, which is near median its own 10-year median of 19.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tongrentang Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tongrentang Co (SHSE:600085) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥35.95, compared to a current price of ¥24.35 — trading 32.3% below its estimated fair value. The current EV-to-EBIT is 17.61, which is near median its 10-year median of 19.45 and 11.7% above the Drug Manufacturers industry median of 15.77. Beijing Tongrentang Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Beijing Tongrentang Co (SHSE:600085), the current EV-to-EBIT is 17.61 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tongrentang Co (SHSE:600085) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tongrentang Co stock appears to be undervalued.
The current stock price of ¥24.35 is trading 32.3% below its estimated GF Value™ of ¥35.95.
GuruFocus considers Beijing Tongrentang Co to be Significantly Undervalued.
Key valuation signals for SHSE:600085:
EV-to-EBIT: 17.61 (near median its 10-year median of 19.45)
GF Value™: ¥35.95 vs. price of ¥24.35 (32.3% below fair value)
Industry Position: 11.7% above the Drug Manufacturers median (#371 of 691)
No single metric tells the full story. See the SHSE:600085 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tongrentang Co Ltd is a China-based company operating in the traditional Chinese medicinal industry. The company produces modern pharmaceuticals and operates retail businesses and medical services. The company's main products consist of Liuwei Dihuang series, Tongren Dahuoluo series, Tongren Niuhuang Qingxin series, Angong Niuhuang series, and Donkey-hide gelatin series. It distributes its products under the brand of Tongrentang.
81GF Score
Get the complete analysis for SHSE:600085
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600085 has been successfully added to your 
